Company: CRL
Filing Date: 2025-04-02
Form Type: DEF 14A
Source: 0001104659-25-030908
Chunk: 97

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-04-02
Form: DEF 14A
Chunk 97
---
 employee’s annual total compensation for 2024 using the same methodology we used for purposes of determining the annual total compensation of our named officers for 2024 (as set forth in the 2024 Summary Compensation Table on page 58of this Proxy Statement). Our CEO’s annual total compensation for 2024 for purposes of the Pay Ratio Rule is equal to the amount reported in the “Total” column in the 2024 Summary Compensation Table found on page 58of this Proxy Statement.

**Pay versus Performance**

Pursuant to SEC rules, the Pay versus Performance disclosure below details compensation for the Company’s CEO and average compensation for the other named executives, both as reported in the Summary Compensation Table and with certain adjustments to reflect compensation actually paid to such individuals in each of the Company’s fiscal years 2024, 2023, 2022, 2021 and 2020. The disclosure also provides information on the Company’s TSR, as well as that of the S&P 500 Health Care Index, on a cumulative basis over the same four fiscal years. The Company’s Net Income is shown for the past four fiscal years, as well as non-GAAP EPS which we consider another important performance measure. A detailed discussion of the Compensation Committee’s decisions regarding the compensation awarded to the named executives for 2024 can be found in the section of this Proxy Statement entitled “Compensation Discussion and Analysis”.

Please see Appendix A to this Proxy Statement for reconciliation of our GAAP EPS to non-GAAP EPS for 2015-2024.

| ​ | ​                         | Year | ​ | ​ | ​ | SummaryCompensationTable Totalfor CEO($) |   |                                     |   | ​ | ​ | ​ | CompensationActually Paidto CEO($)(1) |   |             |   | ​ | ​ | ​ | AverageSummaryCompensationTable Total forOther NamedExecutives($)(2) |   |           |   | ​ | ​ | ​ | AverageCompensationActually paid toOther NamedExecutives($)(1) |   |              |   | ​ | ​ | ​ | Value of Initial Fixed $100Investment Based on(3) |   |     |   |   |   |   |   |   |     |   | ​ | ​ | ​ | Net incomeavailable toCharles RiverLaboratoriesInternational Inc.commonshareholders($) |   |               |   | ​ | ​ | ​ | Non- GAAPEPS($) |   |       |   | ​ | ​ |